1984 Ventures

Most early-stage funds in San Francisco position themselves as generalists with a tilt; 1984 Ventures has spent the better part of a decade demonstrating what that actually looks like in practice. The firm writes seed checks into software companies attacking unsexy verticals, and healthcare is a recurring theme rather than a marketed pillar. Founders meeting 1984 should expect questions about retention, gross margin, and the specific operational pain their software erases for a buyer who does not particularly enjoy buying software. The firm is not a thought-leadership shop; it is a check-writing shop, and it tends to choose companies that look boring on the surface and become very interesting in the cohort data eighteen months in.

1984’s investment thesis centers on vertical software that automates labor-intensive processes inside industries where the buyer is a small or mid-sized business. Healthcare fits that description neatly. Independent practices, dental groups, home health agencies, and outpatient clinics all run on a tangle of legacy systems and human workflow, and the firm has historically gravitated toward companies replacing some piece of that stack with something modern, multi-tenant, and priced as SaaS rather than as enterprise software. The thesis assumes that software-eating-the-world is mostly finished in the obvious categories and that the remaining frontier is in fragmented industries where distribution and retention matter more than technical novelty. Founders pitching pure platform plays or science-heavy biotech will find the conversation short. Founders pitching a focused wedge into a defined customer segment, with credible early commercial traction and a clear understanding of how the buyer evaluates software, will find the firm engaged.

Because this record does not list specific portfolio companies, the public-facing case for 1984 rests on its general pattern rather than named bets. The firm’s published material emphasizes vertical SaaS across healthcare, real estate, financial services, and the long tail of small-business operations. Healthcare positioning lives within Digital Health and Health IT, and the typical 1984 healthcare bet is software for an operator rather than a platform for clinicians or patients. Founders should plan to source comparable references through their own network or through the firm directly during diligence rather than mining a public portfolio list.

Check sizes fall in the one-to-five million dollar range, consistent with a seed-only mandate. 1984 will lead, will price rounds, and is comfortable as the institutional anchor in a round otherwise filled by angels and smaller pre-seed funds. The firm does not typically lead pre-seed rounds and does not chase Series A pricing. Reserves are deployed selectively, usually to defend ownership in companies that have hit clear milestones rather than to bridge through soft quarters. Expect a clean term sheet, standard pro rata, and board observer rather than a board seat in most cases. Founders raising rounds smaller than a million should look elsewhere, and founders raising priced Series A rounds with established metrics will find 1984 too early in the stack.

The firm runs lean. Decision-making is concentrated among the founding partners, which means a founder who gets a meeting is meeting decision-makers from the first conversation. There is no analyst layer running interference, and there is no investment committee theater stretched across multiple weeks. Diligence is direct, often blunt, and tends to move quickly when the partners are interested. When they are not, founders generally know within a week.

The most reliable path in is a warm introduction from a founder the firm has backed. Failing that, a sharp cold email that states the company, the customer, the contract value, and the growth rate in the first three sentences will get read. Avoid jargon-heavy positioning and avoid framing the company as a platform with multiple verticals at seed; 1984 prefers single-wedge specificity. Expect the first call to focus on the customer rather than on the team, and expect the partners to ask uncomfortable questions about churn and sales cycle length.

Founders should know that 1984 is a high-conviction shop that prices on fundamentals rather than narrative. The firm is helpful on go-to-market questions and pricing, less so on clinical or regulatory matters specific to healthcare. Founders building deeply regulated digital health products should pair 1984 with at least one healthcare-specialist co-investor. The firm respects operators and dislikes pageantry, which makes it a comfortable partner for founders who would rather ship than tweet.